Jci_page_head_homepage_01 Jci_page_head_homepage_02
Erica Salvati, Carlo Leonetti, Angela Rizzo, Marco Scarsella, Marcella Mottolese, Rossella Galati, Isabella Sperduti, Malcolm F.G. Stevens, Maurizio D’Incalci, Maria Blasco, Giovanna Chiorino, Serge Bauwens, Béatrice Horard, Eric Gilson, Antonella Stoppacciaro, Gabriella Zupi, Annamaria Biroccio
Published in Volume 117, Issue 11
J Clin Invest. 2007; 117(11):3236–3247 doi:10.1172/JCI32461
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5
Overexpression of TRF2 or POT1 antagonizes RHPS4-induced damage response.

(A) M14 human melanoma cells overexpressing TRF1, TRF2, POT1 or puromycin-resistant gene only (empty) were treated with RHPS4 for the indicated times and processed for immunofluorescence and Western blotting. Histogram showing the increase in γ-H2AX–positive cells compared with the untreated group (upper panel) and a representative Western blot (lower panel) are shown. On average, more than 200 cells were screened per point in independent experiments. Error bars indicate SD. The levels of H2A were used as loading control. (B) M14 cells overexpressing TRF1, TRF2, POT1, or drug resistance (empty) were treated with RHPS4 for 4 days. The surviving fraction was calculated as the ratio of absolute survival of the treated sample to absolute survival of the control sample. (C) Representative images of colony assay.